GeneVault

What GeneVault does

GeneVault (DBA: GeneVault Lifesciences) is a private biomedical data and AI company founded in 2025 and headquartered in Lewes, United States, that addresses the representation gap in genomic medicine—where 96 of 100 genomes behind modern medicine are of European ancestry. The company builds and curates research cohorts from underrepresented populations across Africa, Asia, the Middle East, and Latin America, drawing on a Global BioIntelligence™ Network covering 54M+ patient lives across 50+ countries, supported by 115+ medical facilities and 120 hospitals. Data assets span whole-genome and whole-exome sequencing, multi-omics (proteomics, transcriptomics), longitudinal clinical records, imaging and digital pathology, biospecimen-linked datasets, and deep phenotypic data, all harmonized to common data models and delivered through Trusted Research Environments under GDPR and HIPAA-compliant consent frameworks.

The company's product architecture has two layers. The data layer is the Global BioIntelligence Network, which combines large diverse population cohorts with specialist disease-specific datasets and supports Custom Cohort Curation as a service—fit-for-purpose research cohorts assembled to client protocols across populations, diseases, and therapeutic areas, with the ability to commission new sample collection and prospective assays where data does not yet exist. The AI layer is the Global BioIntelligence™ Platform, a foundation model in development that trains across the network using federated learning (institutions keep data stewardship; only model gradients move between sites), targeting target discovery, variant interpretation, biomarker stratification, protective/resilience genomics, and gene therapy research.

GeneVault operates a sales-led, direct enterprise GTM motion targeting biopharma, biotech, AI/ML companies, and academic research teams. It reports engagement with 5 of Top 10 global pharma and 15+ biopharma, AI, and data platform partners. Revenue mechanics are based on custom cohort curation engagements, with a strategic December 2025 partnership with BC Platforms integrating GeneVault's network into the BC Unify data mastering platform and expanding the combined catchment to 175M+ patient lives across 35+ countries. Pricing is not publicly disclosed.

Name

GeneVault

Website

https://genevault.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

GeneVault curates ancestrally diverse genomic and clinical research cohorts from 50+ underrepresented-population countries, serving biopharma, biotech, AI, and academic clients through a federated learning-enabled biomedical intelligence platform.

Ownership category

akta.pro rank

Product category

Biomedical Data and AI Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Genomic data curation
• Biomedical intelligence
• Custom research cohorts
• Federated learning genomics
• Multi-omic datasets

Headquarters

HQ city

Lewes

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Custom Cohort Curation Services: GeneVault designs and delivers custom research cohorts for biopharma, biotech, AI, and academic teams. Each cohort is built to client protocol specifications across populations, diseases, and therapeutic areas. Where data does not yet exist, they commission new sample collection and prospective assays through their network.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

GeneVault designs and delivers custom research cohorts for biopharma, biotech, AI, and academic teams, drawing on its Global BioIntelligence™ Network of 54M+ patient lives across 50+ countries. Cohorts combine multi-modal genomic, clinical, imaging, and biospecimen-linked data assembled to client-specified inclusion, modality, and endpoint requirements, with the option to commission new sample collection and prospective assays. The company is also developing the Global BioIntelligence™ Platform, an AI foundation model trained via federated learning to enable target discovery, variant interpretation, biomarker stratification, and protective genomics without centralizing source data.

Product overview

GeneVault offers a dual-layer product architecture combining a data network with an AI platform. The Global BioIntelligence™ Network serves as the foundational data layer, sourcing multimodal genomic, clinical, imaging, and biospecimen-linked data from underrepresented populations across 50+ countries. Built on top is the Global BioIntelligence™ Platform, an AI foundation model for target discovery, variant interpretation, and biomarker validation. The company also provides Custom Cohort Curation services for immediate research needs. Together, these components enable representative biomedical intelligence for drug discovery and clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Global BioIntelligence™ Network
• Custom Cohort Curation
• Global BioIntelligence™ Platform

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature4 records

Partnerships

One partnership is on record.

• BC PlatformscoreStrategic or Co-development Partner · 18 December 2025Strategic partnership expanding access to genomic and real-world health data from under-represented populations. GeneVault's network of over 115 medical facilities and 120 hospitals across Asia, the Middle East, Africa, and Latin America is integrated into BC Platforms' BC Unify data mastering platform, expanding BC Platforms' global patient catchment by 48 million patient lives. The combined network now covers 175 million+ patient lives across more than 35 countries spanning multiple therapeutic areas including oncology, immunology, neurology, cardiology, and rare diseases.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BC Platforms: Genomic and real-world data platform with a global data partner network across 35+ countries. Now GeneVault's strategic partner for BC Unify, but operates comparable cohort curation and data mastering services for biopharma, making it both ally and direct competitor.
• DNAnexus: Cloud-based biomedical informatics and multi-omics data platform serving pharma, clinical labs, and researchers with large-scale genomic analysis. Highly comparable as a biomedical data + analysis platform serving similar biopharma buyers.
• Lifebit: Federated genomics and biomedical data platform built around Trusted Research Environments and federated analytics for population-scale genomics. Closely mirrors GeneVault's federated learning and TRE delivery approach.
• Owkin: Federated learning AI company applying multimodal patient data to drug discovery and clinical research with biopharma partners. Comparable buyer set and federated architecture, though focused on oncology and pathology workflows.
• Velsera (formerly Seven Bridges Genomics): Biomedical informatics platform offering multi-omics analysis, clinical genomics pipelines, and data services to pharma and diagnostics labs. Comparable as a multi-modal genomics services and platform vendor to biopharma.

Broad incumbents

• deCODE genetics: Subsidiary of Amgen that runs population-scale human genomics research with deep, genealogically linked datasets. Operates at much larger scale and broader scope, but converges on the same population-genomics and target discovery thesis.
• Verily Life Sciences: Alphabet life sciences subsidiary building large-scale biomedical data platforms (e.g., Baseline) and precision medicine initiatives. Broad incumbent with overlapping ambitions in representative data and AI-driven research.
• Tempus Labs: AI-powered precision medicine company with massive multimodal clinical and molecular data assets serving oncologists and biopharma. Comparable data + AI + biopharma interface, though oriented around US healthcare delivery and oncology.

Emerging players

• Insitro: AI-driven drug discovery company combining induced pluripotent stem cell biology with machine learning and large biomedical datasets. Overlaps at the AI-for-biology intersection, though focused on its own therapeutic pipeline rather than data services.

Others

• UK Biobank: Large-scale population genomics and health data resource used widely by academic and industry researchers. Not a commercial competitor, but a benchmark for population-scale biobanks that biopharma uses for the same target discovery and biomarker use cases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genevault

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneVault